Cellular Biomedicine Group names chief scientific officer
"We are very pleased to welcome Dr. Yao and are confident that his extensive experience in translational science and companion diagnostics development at MedImmune/AstraZeneca and Abbott will continue to expand and enhance our best-in-class R&D enterprise,” Dr. William (Wei) Cao, CEO of CBMG, said.
Yao co-invented 26 filed patents relating to tumor classification, degenerative muscle disease, and autoimmune disease diagnostics and treatment. In addition, he has published more than 60 papers in peer-reviewed translational journals, and has authored or co-authored two books on the subjects of inflammatory and autoimmune diseases and genomic biomarkers.
“During his tenure at MedImmune/AstraZeneca, he successfully built a dynamic, interactive pharmacogenomics team that focused on patient disease segmentation, clinical biomarkers and especially companion diagnostics development for clinical assets in both the immuno-oncology and inflammatory/autoimmune fields," Cao said. "Dr. Yao brings to the company's management team extensive working knowledge in translational medicine strategies as well as a scientific background that will support our research in both inflammatory/autoimmune and especially in the immuno-oncology fields."
Yao received his Ph.D. in Molecular Biology & Biochemistry from the University of Kansas and completed his postdoctoral fellowship at Johns Hopkins University, School of Medicine in Baltimore, Maryland.
"I am very impressed and excited by CBMG's product pipeline, innovative cellular medicine platforms and state-of-the-art facilities,” Yao said. “I feel honored to have the opportunity to work with CBMG's talented scientific research team to fulfill our mission to find new ways to develop and deliver innovative therapies for unmet medical needs in China, where 3.5 million new cancer patients are diagnosed each year. Together with the rest of the leadership team and all the employees of the company, I am confident CBMG will make a social and economic impact toward deadly cancerous diseases as well as debilitating degenerative diseases.”